Cancer Biomarkers Funding Opportunities
Title |
Announcement # | Expiration Date |
|---|---|---|
| Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research | PA-18-902 (R01 Clinical Trial Optional) | 09/08/2021 |
| Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention | PAR-19-251 (R01 Clinical Trial Optional) | 11/09/2021 |
| Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention | PAR-19-252 (R21 Clinical Trial Optional) | 11/09/2021 |
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research | PAR-19-113 (R01 Clinical Trial Optional) | 01/08/2022 |
| Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer | PAR-19-264 (R01 Clinical Trial Optional) | 12/11/2021 |
| Notice of Correction to Application Types Allowed for PAR-20-053, Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection | NOT-CA-20-067 (R01 Clinical Trial Not Allowed) | 01/08/2023 |
| Notice of Special Interest (NOSI): Advancing Head and Neck Cancer Early Detection Research (AHEAD) | NOT-CA-20-031 | 01/08/2022 |
| Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers | NOT-CA-21-028 | 01/08/2024 |
| Notice of Special Interest (NOSI): Single-Cell Proteomics for Interrogating Premalignant and Early Malignant Lesions | NOT-CA-20-044 | 05/08/2023 |
| Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine | PAR-18-841 (U24 - Clinical Trial Optional) | 06/15/2021 |
| Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection | PAR-20-053 (R01 Clinical Trial Not Allowed) | 01/08/2023 |
| Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes | PAR-20-277 (R21 Clinical Trials Not Allowed) | 09/08/2022 |
| Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes | PAR-20-276 (R01 Clinical Trial Not Allowed) | 09/08/2022 |